Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Yttrium-90 ibritumomab tiuxetan and rituximab in patients with Non-Hodgkin lymphoma has completed. The study asses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Lymphoma | Phase 2 | Status: COMPLETED